• Mashup Score: 2
    The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies - 2 year(s) ago

    Section snippetsKey points•Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have led to significant advancements in the management of relapsed/refractory blood cancers with several FDA approved products for multiple myeloma, non-Hodgkin lymphoma and B-cell lymphoblastic leukemia.•In the absence of head-to-head comparisons of CAR T-cell therapy versus bispecific antibodies,…

    Source: www.sciencedirect.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of i_yakoub_agha
      i_yakoub_agha

      RT @CARTTherapy: The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bis... https://t.co/pazRLv2zXB #CART #bmtsm #CARTcell…

  • Mashup Score: 3
    Meral Beksac | Videos & Research | VJHemOnc - 2 year(s) ago

    Meral Beksac speaks exclusively to VJHemOnc on Transplantation for the treatment of multiple myeloma. Watch interviews and discussions with Meral Beksac here.

    Source: VJHemOnc
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of i_yakoub_agha
      i_yakoub_agha

      RT @mbeksac56: @TheEBMT @HaydenpjPatrick @VJHemOnc new videos recorded during EBMT2023 on Multiple Myeloma https://t.co/9GV7WfnYgs

  • Mashup Score: 0
    PROGRAM 2023 - 2 year(s) ago

    You can download the latest version of the program here Wednesday September 6th, 2023 08:00 – Welcome and registration 09:45 – Introduction Frédéric Boiron, General Director of Lille Un…

    Source: CAR T Day
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of i_yakoub_agha
      i_yakoub_agha

      Registration is going well for the 7th edition international meeting ⁦CARTday ⁩ in Lille. ⁦@LilleInfinite⁩ ⁦@CHU_Lille⁩ ⁦@univ_lille⁩ ⁦@SFGM_TC⁩ ⁦@at_Mitralab⁩ . For more details please follow ⁦@CARTDAY110623⁩ https://t.co/iNydo1zTw6

Load More